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Abstract
Background: Herpes simplex virus type 2 (HSV-2) is a common co-infection among HIV-infected adults that is
hypothesized to accelerate HIV disease progression.
Methods: We searched Medline, EMBASE, relevant conference proceedings (2006–12) and bibliographies of identified
studies without language restriction for cohort studies examining the impact of HSV-2 on highly active antiretroviral
therapy-untreated HIV disease in adults. The exposure of interest was HSV-2 seropositivity or clinical/laboratory markers
of HSV-2 activity. The primary outcome was HIV disease progression, defined as antiretroviral initiation, development of
AIDS/opportunistic infection, or progression to CD4 count thresholds (≤200 or ≤350 cells/mm3). Secondary outcomes
included HIV plasma viral load and CD4 count.
Results: Seven studies were included. No definitive relationship was observed between HSV-2 seropositivity and time
to antiretroviral initiation (n=2 studies), CD4≤350 (n=1), CD4≤200 (n=1), death (n=1), viral load (n=6) or CD4 count
(n=3). Although two studies each observed trends towards accelerated progression to clinical AIDS/opportunistic
infection in HSV-2 seropositives, with pooled unadjusted hazard ratio=1.85 (95% CI=1.12,3.06; I2=2%), most OIs
observed in the study for which data were available can occur at high CD4 counts and may not represent HIV
progression. In contrast, a single study HSV-2 disease activity found that the presence of genital HSV-2 DNA was
associated with a 0.4 log copies/mL increase in HIV viral load.
Conclusions: Despite an observation that HSV-2 activity is associated with increased HIV viral load, definitive evidence
linking HSV-2 seropositivity to accelerated HIV disease progression is lacking. The attenuating effects of acyclovir on HIV
disease progression observed in recent trials may result both from direct anti-HIV activity as well as from indirect
benefits of HSV-2 suppression.
Keywords: Herpes simplex virus, Human immunodeficiency virus, Disease progression, Viral load, CD4 count,
Seropositivity, Systematic review
Background
Herpes simplex virus type 2 (HSV-2) is a common
pathogen that co-infects over half of HIV-infected adults
[1], and may accelerate HIV disease by increasing
plasma HIV viral load [2,3]. Some authors therefore sug-
gest that HIV-infected patients be routinely screened for
HSV-2 antibodies, and that co-infected individuals be of-
fered chronic suppressive HSV therapy [4]. Indeed, two
recent clinical trials among HIV, HSV-2 co-infected
adults in Sub-Saharan Africa have demonstrated a mo-
dest attenuation in HIV disease progression with the
anti-HSV medication acyclovir 400mg twice daily [5,6].
Two potential mechanisms for this finding have been
advanced. The leading hypothesis is that by suppressing
HSV-2 activity, acyclovir reverses the adverse impact of
HSV-2 co-infection on HIV disease progression. More
recently, however, in vitro data have suggested that
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acyclovir may have direct anti-HIV activity [7,8], raising
the possibility that anti-HIV effects may have also con-
tributed to the trial findings.
To further investigate these issues, and to inform
the counseling of HIV patients regarding the impact of
co-infection on their HIV disease, we undertook a sys-
tematic review of observational cohort studies addres-
sing the impact of HSV-2 on longitudinal measures of
HIV disease progression. The primary objective was to
summarize the impact of HSV-2 co-infection on anti-
retroviral therapy (ART)-untreated HIV disease progres-
sion among HIV-1-infected adults. Secondary objectives
were to summarize the relationship between HSV-2 co-
infection (including both seropositivity and measures of
HSV-2 disease activity) and HIV plasma viral load and
CD4 count.
Methods
Methods of the analysis and inclusion criteria were spe-
cified in advance and documented in a protocol available
from the authors.
Study and participant criteria
Cohort studies examining the impact of HSV-2 co-
infection on progression of ART-untreated HIV disease
over ≥6 months, HIV plasma viral load, or CD4 count
were considered for inclusion. Studies must have in-
cluded HIV-1-infected adults not using ART (mono- or
combination therapy). However, a single study including
short-course zidovudine for the prevention of mother-
to-child HIV transmission (week 34–36 of pregnancy
until delivery) was included, because this short duration
of exposure was unlikely to impact on disease progres-
sion over the 18 month median duration of follow-up.
Participants must not have been using chronic suppres-
sive anti-HSV therapy (acyclovir, valacyclovir and/or
famciclovir) or other agents with anti-HSV activity (eg.
ganciclovir, valganciclovir, cidofovir, foscarnet).
Exposure
The exposure of interest was HSV-2 co-infection. Be-
cause HSV-2 is incurable and frequently asymptomatic,
this exposure can only be accurately ascertained through
HSV type-specific serologic assays that detect antibody
to glycoprotein G. Studies using less accurate serologic
assays such as those based on whole virus or crude anti-
gen preparations were excluded.
Alternative laboratory measures of HSV-2 disease ac-
tivity with good specificity were also examined, including
viral culture and viral shedding detected by polymerase
chain reaction (PCR), but studies using clinical history
only were excluded because such anamnestic methods
are of limited sensitivity.
Outcome measures
The primary outcome of interest was HIV disease pro-
gression. Because multiple valid measures of this concept
exist and have changed over time, it was important to in-
clude different definitions of this outcome and consider
each one separately, including a) ART initiation b) deve-
lopment of AIDS or first opportunistic infection (OI), c)
progression to CD4 count ≤200 cells/mm3, and d) pro-
gression to CD4 count ≤350 cells/mm3. Secondary out-
comes were HIV plasma viral load and CD4 count since
these are critical laboratory markers for assessing HIV dis-
ease progression. Since viral loads fluctuate around a
stable ‘set-point’ in individual patients, the main viral load
measures of interest were time-averaged viral loads col-
lected over ≥6 months, or changes in viral load at author-
defined time points. The main CD4 count measure of
interest was the rate of change per unit time. Within-
patient changes in viral load and CD4 count associated
with HSV-2 disease activity over time were also collected.
Search methods for identifying studies
Eligible publications were identified through electronic
searches of Medline (January 1950-April week 3, 2013)
and EMBASE (1980–2013 week 16) followed by removal
of duplicate citations. Details of the Medline search stra-
tegy are provided in Additional file 1. Manual searches of
the following conference proceedings from 2006–2012
were also conducted: Conference on Retroviruses and
Opportunistic Infections, International AIDS Society Con-
ference on HIV Pathogenesis, Treatment and Prevention;
IAS World AIDS Conference, Interscience Conference
on Antimicrobial Agents and Chemotherapy, Infectious
Diseases Society of America Annual Meeting, and the
International Society for Sexually Transmitted Disease
Research. Reference lists of identified articles were also
used. No language restrictions were applied. We did not
search grey literature or dissertation indices.
Selection of studies and data extraction
All publications and abstracts that appeared to meet
eligibility criteria were retrieved. Two authors (DHST,
KM) independently assessed studies for inclusion in
an unblinded standardized manner, and independently
extracted data onto standardized forms, with disagree-
ments resolved by consensus and involvement of other
authors. Information was extracted from each included
study on: 1) characteristics of study participants, inclu-
ding geographic location, sex, baseline CD4 count, base-
line HIV viral load, 2) methods of HSV-2 ascertainment,
including details of laboratory assays as appropriate,
and 3) outcome measures, including time-to-event data,
CD4 counts, and viral load, along with the follow-up
time for the study. Attempts to contact authors to sup-
ply missing data were made on up to three occasions; if
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information was not available, data were assumed to be
missing at random.
Assessment of risk of bias
Assessment of risk of bias was performed for each study
to explain heterogeneity in results and perform sensi-
tivity analyses. A list of important study features that
may impact on bias was developed by reviewing the
STROBE statement and other published criteria [9,10].
This approach was used because a previously published
systematic review of tools for assessing the quality and
susceptibility to bias in observational studies was unable
to identify a single obvious candidate tool for this pur-
pose, and similarly references the STROBE statement as
a valuable starting point for quality assessment [11]. The
risk of bias for each study was assessed systematically
using the criteria in Table 1. Assessments were not
blinded to articles for feasibility reasons.
Analysis
The primary expected summary measure relating HIV
disease progression to HSV-2 co-infection was the ha-
zard ratio. Where appropriate, hazard ratios were pooled
in meta-analyses using random effects models, with
weighting of studies according to the DerSimonian-Laird
method. Cochran's Q test was used to test for hetero-
geneity between studies at the 0.10 level of significance.
The I-squared statistic was used to quantify the degree
of heterogeneity. For viral load and CD4 count out-
comes, meta-analysis was planned using the weighted
mean difference, but available data were inappropriate
for analysis due to differences in study methodology and
reporting. Formal tests to assess for the possibility of
publication bias were not performed given the variety of
ways in which outcomes were reported. All statistical
analyses were performed using Review Manager version
5. Data were synthesized descriptively when not appro-
priate for meta-analysis.
Subgroup analyses were planned to examine incident
rather than prevalent HSV-2 infection, incident versus
prevalent HIV infection, geographic region, HSV-1 co-
infection, and use of any antiretrovirals. Sensitivity ana-
lyses were planned in which the results of studies would
be considered in groups, according to the risk of bias.
Results
Studies included in the review
The electronic search strategy identified 1052 articles
through MEDLINE and 1531 through EMBASE (Figure 1).
Of these, 38 appeared to meet eligibility criteria. Two po-
tentially eligible articles were identified from reference
lists, and two more from conference proceedings. Of the
resulting 42 studies, 7 were ultimately included (Table 2)
[12-18]. Thirty-five papers were excluded because they
were cross-sectional in design (n=13), addressed a dif-
ferent research question (n=7), included ART-treated
Table 1 Criteria for assessing the risk of bias in included studiesa
Criterion Risk of bias
Low Moderate High
Eligibility · Recruited from general HIV-infected population,
eg. HIV clinics
· Recruited from moderately selected
population, eg. STI clinics
· Highly selected population
(eg. FSW, active GUD)
· Unclear selection criteria applied
HSV-2
ascertainment
· High quality type-specific serology assay · Culture-based diagnosis · Methods unclear
· PCR assay · Clinical diagnosis
Endpoint
ascertainment
· Similar between groups · Similar between groups · Methods unclear
· Regular timing · Irregular timing
Confounding · Accounted for ART, and · Some of these confounders
accounted for
· None of these confounders
accounted for or unclear
· Accounted for acyclovir, and
· Accounted for CD4/stage of HIV disease
Analysis · Sample size or power calculation done, and · No concerns with analysis · Problems identified with analysis
· No concerns with analysis
Attrition · Minimal attrition (<10%) and · Moderate attrition (10-20%) · High attrition (>20%)
· Attrition explained · Attrition not explained
OVERALL · Most items at low risk of bias, including both
HSV-2 ascertainment and confounding
· Most items at low to moderate
risk of bias
· Most items at moderate risk of bias
· Not more than two items at moderate risk
of bias
· No item at high risk of bias · At least one item at high risk
of bias
aFSW = female sex workers; GUD = genital ulcer disease; STI = sexually transmitted infection.
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patients (n=7) were methodologic in nature (n=2), were
duplicate publications (n=2), used clinical history (n=2)
or a poor quality serologic assay (n=1) to define HSV-2
status, or included only patients receiving acyclovir (n=1).
Assessment of risk of bias
The quality of included studies was variable (Table 2).
Eligibility criteria were generally appropriate and well
described, with most included studies conducted among
unselected cohorts of HIV-infected adults. All studies
employing serology to ascertain HSV-2 status used high
quality assays, although the timing of HSV-2 testing
relative to the period of follow-up was unclear in one re-
port [15]. The single study employing a marker of HSV-
2 disease activity in the analysis used HSV-2 polymerase
chain rection (PCR) to detect the presence of reactiva-
ting virus in a cohort of HSV-2 seropositive participants
[16]. Outcome assessments were general well performed,
although their timing was irregular or unclear in some
reports [14,15]. Several studies did not report on or ad-
equately adjust for relevant confounders including anti-
HSV medications [12,15,17,18], and baseline CD4 count
[15]. No study included a formal sample size calculation,
and attrition was inconsistently described, but analytic
techniques were generally appropriate.
For studies at moderate or high risk of bias, a qualita-
tive assessment was made regarding the likely direction
of bias(es). For instance, studies failing to systematically
account for anti-HSV medications may be biased to-
wards the null [12,15,17,18].
Studies evaluating HSV-2 seropositivity
Disease progression outcomes
Four studies evaluated the relationship between HSV-2
seropositivity and HIV disease progression outcomes
(Table 3). Two considered ART initiation as an end-
point, and neither observed an association with HSV-2
seropositivity; these studies were at moderate [12] and
high [15] risk of bias respectively but the likely direction
of this bias was difficult to ascertain. In addition, diffe-
rent definitions of ART were used, as shown. Data were
therefore not appropriate for meta-analysis [12,15].
The latter of these studies also reported on the pro-
portion of individuals reaching a CD4 count ≤350 cells/
mm3 or 18% at various time points and found no dif-
ference according to HSV-2 serostatus [15]. A study
among postpartum women in Kenya similarly reported
no statistically significant relationship between HSV-2
and time to CD4 count ≤200 cells/mm3, nor a relation-
ship with the time to death from any cause. There was
moderate risk of bias towards the null in this study be-
cause of some acyclovir use [17]. Again, differences in
the outcome definitions precluded meta-analysis.
Two studies considered AIDS or OI as endpoints: the
Kenyan study described above [17], and an Italian study
of HIV seroconverters at high risk of bias of uncertain
impact [18]. Both used clinical endpoint definitions and
each observed a trend towards an accelerated time to
these events with HSV-2 seropositivity [17,18]. Meta-
analysis was conducted to pool the univariate hazard ra-
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• 1 conference abstract
• 6 full articles
• 7 different research question
• 7 included ART-treated patients
• 2 methodologicpapers
• 2 same studyb
• 2 defined HSV-2 using history only
• 1 defined HSV-2 using poor quality assay
• 1 all on acyclovir
a Reasons are mutually exclusive. b One in two articles, one abstract followed by full article
Figure 1 Flow chart for identifying studies.
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Table 2 Characteristics of included studies and assessment of the risk of biasa
Study Study Characteristics Assessment of the risk of bias


























USA 367 92 499 NR NR Low Moderate Moderate High Moderate Moderate High ?
Nagot
2008
Women, Burkina Faso 140 0 443 4.48 12
weeks
Moderate Low Low Low Moderate Low Low N/A
Roxby
2011
Pregnant women, Kenya 296 0 422 4.75 18
months
Moderate Low Low Moderate Moderate Moderate Moderate ↓
Suligoi
2001
HIV sero-converters, Italy 380 78 NR NR 7.8 years Low Low Moderate High Moderate High High ?
aMedian values are reported unless noted otherwise. When values were not reported for overall population, a weighted average was taken.
bN reported for patients included in relevant comparisons only.



















statistically significant pooled HR=1.85 (95% CI=1.12,3.06;
n=676 participants; I2=2%, Figure 2). However, this pooled
analysis does not explicitly adjust for an important poten-
tial confounder, the stage of HIV disease at which indivi-
duals began observation. In the Kenyan study, an analysis
adjusted only for baseline CD4 count produced an ad-
justed HR=1.16 (95% CI=0.52,2.56) [17], whereas the uni-
variate hazard ratio from the Italian study, an inception
cohort which inherently accounted for participants’ date
of HIV seroconversion, was 1.68 (95% CI=1.19,2.37) [18].
Of note, it was not possible to conclusively exclude the
possibility of some ART use in the latter study, in that it
was conducted between 1983–1998 in Italy. Of further
note, most (at least 44/51) of the OIs observed in the
Kenyan study were conditions that can arise at any CD4
count including tuberculosis and zoster, which are
Table 3 Impact of HSV-2 seropositivity on HIV disease progressiona
Study Population N HSV-2
Ascertainment
Results






87 Serology: Western Blot Initiation of
HAART
NR NR aHR = 1.3c,








18 months 9 months p = 0.10 ↔
(range = 1,156) (range = 1,96)
271 Proportion with
CD4≤350 or 18%
at 1 year of
follow-upe
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Suligoi 2001 Italy 380 Serology: Pockit AIDS NR NR HR = 1.68, (95%
CI = 1.19,2.37),
Adjustedg
HR = 1.13, (95%
CI = 0.76, 1.70)
Faster?
aCI = confidence interval, HAART = highly active antiretroviral therapy, HR = hazard ratio, NR = not reported, OI = Opportunistic infection, OR = odds ratio.
bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting
statistical significance.
cAdjusted for adenovirus 5 immunity, region, circumcision status, age, race, HLA group, trial intervention assignment (vaccine / placebo).
dIncludes any ART (monotherapy, non-HAART combination therapy and HAART).
eDefined as CD4 count <350 cells/mm3 or 18%.
fAdjusted for baseline CD4 count.





Heterogeneity: Tau² = 0.01; Chi² = 1.02, df = 1 (P = 0.31); I² = 2%
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HSV-2 slows HIV diseaseHSV-2 accelerates HIV
Figure 2 Forest plot of the impact of HSV-2 seropositivity on time to opportunistic infection/AIDS (unadjusted analysis).
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arguably less indicative of HIV disease progression than
other AIDS-defining illnesses (ADI) [17]; data on the types
of ADI in the Italian study were not available. In conclu-
sion, while these two studies suggest a relationship be-
tween HSV-2 seropositivity on hastening progression to
first OI or clinical AIDS, other available data do not sup-
port a relationship between HSV-2 serostatus and HIV
disease progression overall.
Plasma viral load
Five studies compared plasma HIV viral load according to
HSV-2 serostatus (Table 4). Of the four reporting on
prevalent HSV-2 seropositivity, one used repeated mea-
sures regression models to assess viral loads over roughly
half a year [13], two reported changes in viral load at fixed
time points [15,17], and one used linear regression to
assess the viral load set point, defined as the numeric aver-
age of the 8- and 12-week post-infection levels [12]. None
observed a statistically significant association with in-
creased HIV viral load, including the Kenyan study des-
cribed above which did observe an accelerated time to OI
[17]. Similarly, no effect on change in viral load was
observed in the single study examining incident HSV-2
seropositivity, although the sample size was small with
only 9 seroconverters [14].
CD4 count
Three studies examining the relationship between preva-
lent HSV-2 seropositivity and CD4 count reported con-
flicting results: a marginally slower rate of CD4 count
decrease among HSV-2 infected American women in a
study at moderate risk of bias towards the null [12], no
difference in rates of CD4 count change in a Kenyan
study at moderate risk of bias towards the null [17], and
larger decreases in CD4 counts after fixed time points in
an American study in which several methodologic issues
may have had conflicting biases (Table 5) [15]. Incident
HSV-2 seropositivity was associated with no change in
CD4 counts based on one study [14].
Studies evaluating HSV-2 activity
There were no studies that met our eligibility criteria that
described the relationship between HSV-2 disease activity
and longitudinal measures of HIV disease progression. A
single study examined the impact of HSV-2 activity on
plasma HIV viral load among HSV-2 seropositive women
in Burkina Faso, and observed modest increases of 0.4 log
copies/mL associated with the presence of genital HSV-2
DNA over a 6-visit, 12-week follow-up period [16].
Subgroup and sensitivity analyses
Because most results could not be pooled in meta-
analyses, quantitative subgroup and sensitivity analyses
were not performed, and there were not enough studies
available to provide meaningful subgroup analyses based
on prespecified criteria (incident HSV-2, incident HIV,
geographical location). No studies examined the impact
of HSV-1 co-infection. Restricting the review to studies
at low risk of bias left only three studies, which collec-
tively described a lack of association between HSV-2
seropositivity and either HIV viral load or CD4 count
[13,14], but a positive association between laboratory
Table 4 Impact of HSV-2 seropositivity on viral loada
Study Population N HSV2
Ascertainment
Outcome: VIRAL LOAD (in log10 copies/mL)
Outcome HSV2 pos HSV2 neg Difference Effectb






88 Serology: WB VL setpoint (mean of 8 &
12 week post-infection VL)c
+0.3





















to HSV2 by WB







p = 0.57 ↔




USA 271 Serology: Focus Change in VL at 1 year +0.17 +0.08 +0.1, p = 0.61 ↔
221 Change in VL at 3 years +0.46 −0.09 +0.6, p = 0.44 ↑?
Roxby 2011 Postpartum
women, Kenya
296 Serology: Focus Change in VL over mean
18 months
NR NR No difference ↔
aCI = confidence interval, GUD = genital ulcer disease, MSM = men who have sex with men, OR = odds ratio, SD = standard deviation, VL = viral load,
WB = Western Blot.
bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting
statistical significance.
cBased in part on imputed data as 47% of VL observations missing.
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confirmed presence of genital HSV-2 and increased
plasma viral load [16].
Discussion
This systematic review did not identify conclusive evi-
dence of an association between HSV-2 seropositivity
and HIV disease progression, changes in plasma viral
load, or CD4 cell count. Although two studies observed
trends towards an accelerated progression to clinical
AIDS or first OI [17,18], most of the OIs observed in
the study for which data were available can occur at high
CD4 counts and may not represent progression of HIV
[17]; further, compelling data linking HSV-2 seropositi-
vity to other disease progression outcomes were lacking.
One study found evidence that HSV-2 disease activity, de-
fined as the presence of genital HSV-2 using PCR, is asso-
ciated with increased viral load among HSV-2 seropositive
individuals.
These observations must be considered in light of un-
equivocal data from interventional studies linking anti-
HSV medications to decreased HIV viral loads and
attenuated disease progression. In a meta-analysis of
seven randomized trials of acyclovir or valacyclovir
among HAART-untreated, HIV, HSV-2 co-infected per-
sons, the summary treatment effect for HSV-2 suppres-
sion on plasma HIV RNA was −0.33 log copies/mL
(95% CI=−0.56,-0.10) [19]. Further, this effect appears to
be dose-responsive; stratification by drug demonstrated
greater decreases in viral load with valacyclovir than
acyclovir in the meta-analysis [19]. A meta-analysis
from the pre-HAART era suggested that >3200 mg per
day of acyclovir offered a significant survival benefit
(hazard ratio, HR for mortality=0.78, 95% confidence
interval, CI=0.65,0.93) [20], but it is unclear whether the
improved survival was only related to eradication of
herpesviruses (including HSV and CMV) or whether
there could have been a secondary impact on HIV repli-
cation. Most recently, in the Partners in Prevention
HSV/HIV Transmission Study of acyclovir 400 mg
twice daily, the HR for the composite primary endpoint
of CD4 count ≤200 cells/mm3, antiretroviral initiation,
or death from non-traumatic causes, was 0.84 (95%
CI=0.71,0.98) [6]. In a similar trial from the Rakai dis-
trict of Uganda, the composite primary endpoint was
slightly different (CD4 count ≤250 cells/mm3 or the
occurrence of any WHO stage 4 clinical event not in-
cluding esophageal candidiasis), and the HR associated
with acyclovir use was 0.75 (95% CI=0.58,0.99) [5].
Indirect benefits of HSV-2 suppression are thought to
primarily underlie these effects, and the observation of
increased HIV viral load with HSV-2 disease activity in
the Burkina Faso study supports this hypothesis [16].
But how might these findings be reconciled with the lack
of convincing evidence of an effect of HSV-2 seroposi-
tivity on markers of HIV disease progression observed in
this review? One explanation may be that all HSV-2
serology assays have limited sensitivity in early infection
[21,22], and no studies repeated testing on seronegative
participants to test for seroconversion. However, the
magnitude of this effect should be minimal, given the re-
ported incidence of HSV-2 in HIV-infected populations
of 1.8 to 7.3 per 100 person-years [14,23]. A more plau-
sible hypothesis is that considering only HSV-2 serosta-
tus ignores the duration and activity of HSV-2 infection.
Since the natural history of HSV-2 is characterized by a
decreasing frequency of reactivations over time [24-27],
overrepresentation of individuals with longstanding in-
fection may produce HSV-2 seropositive cohorts with
relatively inactive HSV-2. The magnitude of HIV upreg-
ulation by HSV-2 may instead depend on the degree
of HSV-2 activity and be greatest during symptomatic
herpes, as has been observed elsewhere [28]. Studies of
Table 5 Impact of HSV-2 seropositivity on CD4 counta
Study Population N HSV2
Ascertainment
Outcome: CD4 COUNT (in cells/mm3)
Outcome HSV2 pos HSV2 neg Difference Effectb
Studies in acute HIV seroconverters






Change in CD4 after vs
before HSV-2





p = 0.36 ↔
Studies in chronic HIV infection
Crum-Cianflone
2006
USA 271 Serology: Focus Change in CD4 at 1 year −116 +14 −130,
p=0.003
↓










aCI = confidence interval, IQR = interquartile range, NR = not reported, MSM = men who have sex with men, WB = Western Blot.
bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting
statistical significance.
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HSV-2 seropositivity cannot distinguish between periods
of viral latency and reactivation, such that any impact
of HSV-2 activity on HIV replication may have been
diluted in some of the studies we included. In support of
this notion, symptomatic genital ulcer disease of any
etiology has been linked to accelerated HIV disease pro-
gression [2,17,29]. It is also likely that the positive rela-
tionship between HIV viral load and HSV-2 activity is
partially confounded by HIV-related immunosuppression.
In contrast to the 0.4 log copies/mL increase in viral
load associated with HSV-2 activity in the Burkinabé
study [16], a recent randomized trial observed larger
viral load decreases of −1.23 log copies/mL using valacy-
clovir 1.5g twice daily [30]. Taken together, these ob-
servations suggest that reversing HSV-2 associated
increases in HIV viral load may not be the only mechan-
ism by which such drugs attenuate HIV. Direct anti-
retroviral effects of acyclovir and related drugs may also
contribute, as have been observed in vitro by two inde-
pendent groups [7,8]. Arguing against this possibility,
however, an evaluation of 168 HIV infected clinical trial
participants receiving either acyclovir 400 mg twice daily
or valacyclovir 500 mg twice daily for 8–104 weeks failed
to identify the V75I reverse transcriptase mutation that
confers acyclovir resistance most commonly observed
in vitro [31]. The purported explanation for this negative
finding is the considerably lower concentrations of acy-
clovir achieved in the clinical setting compared with the
laboratory studies. Still another possibility is that acyclovir
could attenuate HIV disease progression by decreasing
HSV-2-related immune activation, although two studies
have recently shown no benefit of valacyclovir on a variety
of inflammatory markers [32,33]. Further data are needed
to clarify the relationship between HSV-2, anti-herpes
medications and HIV viral load.
Strengths of this systematic review include our broad,
multi-modality search strategy and the lack of language
restrictions. There are also limitations that warrant con-
sideration, and the robustness of our conclusions is
dependent on the available evidence. First, few studies
addressed our primary research question, restricting our
ability to quantify the impact of HSV-2 seropositivity on
HIV disease progression. Second, the measures used to
define HSV-2 seropositivity and HSV-2 activity differed
between studies. Although most type-specific serology
assays have high, comparable levels of sensitivity and
specificity when compared against the Western Blot gold
standard, uncertainty regarding the optimal cutoff values
in different populations and limitations of all assays in
detecting early HSV-2 seroconversion may result in mis-
classification [34]. Third, our assessment of the risk of
study bias was necessarily subjective. However, we sys-
tematically applied criteria based on the STROBE state-
ment as has been advised elsewhere, because of the lack
of a single obvious candidate tool for this purpose in
systematic reviews of observational studies [11]. Fourth,
differences in study populations and HIV clades may ex-
plain some observed differences between studies. Finally,
inadequate control for confounding by variables such as
anti-HSV drug use could have biased studies towards
the null; further, no study systematically excluded HIV
long-term non-progressors.
Conclusions
This systematic review found no definitive evidence that
HSV-2 seropositivity is associated with accelerated HIV
disease progression in HAART-untreated persons, and
modest evidence that HSV-2 disease activity is asso-
ciated with increased HIV viral load. Attenuating effects
of acyclovir on HIV disease progression observed in re-
cent trials may result both from direct anti-HIV activity
as well as from indirect benefits of HSV-2 suppression.
Further research is needed to clarify the exact mecha-
nisms by which HIV, HSV-2 and drugs like acyclovir
interact.
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